Charles Lance Cowey

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

James Larkin, Michele Del Vecchio, Mario Mandalà et al. · Clinical Cancer Research · 2023 · 180 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.

Adnan Khattak, Jeffrey S. Weber, Tarek Meniawy et al. · Journal of Clinical Oncology · 2023 · 68 citations

Medicine, Oncology, Pharmacology +14

Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.

Jeffrey S. Weber, Muhammad Adnan Khattak, Matteo S. Carlino et al. · Journal of Clinical Oncology · 2024 · 35 citations

Medicine, Oncology, Pharmacology +16

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

Paolo A. Ascierto, Michele Del Vecchio, Barbara Merelli et al. · New England Journal of Medicine · 2025 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +17